A 36-years-old man was diagnosed with Philadelphia positive B-cell acute lymphoblastic leukemia (ALL) with no central nervous system (CNS) involvement in early March 2019. He was treated with daily dasatinib, weekly vincristine, and dexamethasone twice weekly. He was then treated with methotrexate and Ara-c and achieved complete molecular remission by polymerase chain reaction (PCR). Subsequently, he underwent allogeneic peripheral blood matched sibling HCT with cyclophosphamide (Cy) and total body irradiation (TBI) myeloablative conditioning (MAC) in July 2019. The course was complicated by grade II, steroid-responsive, acute gut graft versus host disease (GVHD), and cytomegalovirus (CMV) reactivation. He remains in complete molecular remission, and cyclosporine (CSA) was discontinued in March 2020 (day 237 post HCT). He is currently on prophylactic acyclovir and Bactrim. Early June 2020, he developed low grade fever of 37.9 Celsius (C) and fatigue. He tested positive for SARS-Cov2 infection by real - time Polymerase Chain Reaction (RT-PCR) on June 11, 2020 (day 323 post HCT). He did not have any further fever after June 12. He only received as needed acetaminophen. Repeat nasal SARS-Cov2 PCR on August 20, 2020, was negative, and his SARS-Cov2 total antibody test was reactive.